JO
ASND icon

John Overdeck’s Ascendis Pharma A/S ASND Stock Holding History

John Overdeck’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$373K Hold
1,400
– – ﹤0.01% 4373
2026
Q1 		$320K Buy
+1,400
New +$314K ﹤0.01% 4032

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

John Overdeck's ASND Position: Q2 2026 in Review

John Overdeck increased its Ascendis Pharma A/S (ASND) stake by 39% in Q2 2026, buying an estimated $20M and bringing the position to 305,803 shares worth $81.6M. The position accounts for 0.06% of the portfolio, ranked #376.

John Overdeck first reported a position in ASND in Q1 2024 and has held it in 10 quarters since. 310 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • John Overdeck held 305,803 shares of Ascendis Pharma A/S worth $81.6M as of Q2 2026.
  • John Overdeck bought 85,462 Ascendis Pharma A/S shares in Q2 2026, an estimated $20M.
  • Ascendis Pharma A/S made up 0.06% of John Overdeck's portfolio in Q2 2026, its #376 holding.
  • John Overdeck first reported a position in Ascendis Pharma A/S in Q1 2024 and has held it in 10 quarters since.
  • 310 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.